User:Kevin Buadlart Dagbay

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (11:30, 17 March 2013) (edit) (undo)
 
(19 intermediate revisions not shown.)
Line 1: Line 1:
-
'''Bold text'''One of the [[CBI Molecules]] being studied in the [http://www.umass.edu/cbi/ University of Massachusetts Amherst Chemistry-Biology Interface Program] at UMass Amherst and on display at the [http://www.molecularplayground.org/ Molecular Playground].
+
 
-
<Structure load='3QNW ' size='500' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' />PhD Chemistry Student
+
One of the [[CBI Molecules]] being studied in the [http://www.umass.edu/cbi/ University of Massachusetts Amherst Chemistry-Biology Interface Program] at UMass Amherst and on display at the [http://www.molecularplayground.org/ Molecular Playground].
 +
<Structure load='3QNW ' size='500' frame='true' align='right' caption='Caspase-6 with Z-VAD-FMK, an inhibitor of caspase-6 activity' scene='caspase-6' />PhD Chemistry Student
University of Massachusetts Amherst
University of Massachusetts Amherst
Protein Regulation/Structural Biology of Caspase
Protein Regulation/Structural Biology of Caspase
-
Molecular Playground banner: Caspase-6, a protease that is implicated in neurodegenerative disease including Alzheimer's and Huntington
+
Molecular Playground banner:<scene name='User:Kevin_Buadlart_Dagbay/Active_site_with_z-vad-fmk/1'>Caspase-6, a protease that is implicat in neurodegenerative disease including Alzheimer's and Huntington.</scene>
-
<scene name='CRABP_I_(_Cellular_Retinoic_Acid_Binding_Protein_)/1cbs_molecularplayground/21'>Molecular Playground: CRABP I with retinoic acid</scene>
 
- 
-
Molecular Playground banner: Caspase-6 with Z-VAD-FMK, an inhibitor of caspase-6 activity.
 
- 
-
Introduction
 
 +
==Caspase-6 and Neurodegeneration==
Cysteine aspartate proteases (caspases) play several key roles in cellular development, homeostasis, and a wide range of diseases. These proteases are normally expressed in cells as inactive precursor zymogens and get activated during processes such as cellular death pathway known as apoptosis [http://www.nature.com/onc/journal/v23/n42/full/1207963a.html]. Caspase-6 is particularly interesting since it has been implicated in neurodegenerative diseases including Alzheimer’s and Huntington’s Disease. Alzheimer’s Disease is the major cause of cognitive and cerebral deterioration in older adults. Caspase-6 has been shown to cut amyloid precursor protein (APP), at position 720 leading to the toxic fragment Jcasp, which is one of the fragments possibly responsible for causing the disease morphology [http://jcs.biologists.org/content/113/11/1857]. Specific amino acid sequence (IVLD586G) is recognized by caspase-6 in mice with Huntington’s disease that give rise to the development of the behavioral and neuropathological features of the disease [http://www.ncbi.nlm.nih.gov/pubmed/9535906] [http://www.jbc.org/content/275/26/19831.abstract]. Mutation of the caspase-6 site in mice model with Alzheimer’s and Huntington’s disease provides protection from the neural dysfunction, suggesting a causal relationship between caspase-6 cleavage and neurodegeneration.
Cysteine aspartate proteases (caspases) play several key roles in cellular development, homeostasis, and a wide range of diseases. These proteases are normally expressed in cells as inactive precursor zymogens and get activated during processes such as cellular death pathway known as apoptosis [http://www.nature.com/onc/journal/v23/n42/full/1207963a.html]. Caspase-6 is particularly interesting since it has been implicated in neurodegenerative diseases including Alzheimer’s and Huntington’s Disease. Alzheimer’s Disease is the major cause of cognitive and cerebral deterioration in older adults. Caspase-6 has been shown to cut amyloid precursor protein (APP), at position 720 leading to the toxic fragment Jcasp, which is one of the fragments possibly responsible for causing the disease morphology [http://jcs.biologists.org/content/113/11/1857]. Specific amino acid sequence (IVLD586G) is recognized by caspase-6 in mice with Huntington’s disease that give rise to the development of the behavioral and neuropathological features of the disease [http://www.ncbi.nlm.nih.gov/pubmed/9535906] [http://www.jbc.org/content/275/26/19831.abstract]. Mutation of the caspase-6 site in mice model with Alzheimer’s and Huntington’s disease provides protection from the neural dysfunction, suggesting a causal relationship between caspase-6 cleavage and neurodegeneration.
-
 
+
==Structure and Regulation==
-
Cellular Retinoic Acid Binding Proteins('''CRABPs''') are small intracellular proteins (15.5
+
The structure of caspase-6 [http://www.ncbi.nlm.nih.gov/pubmed/19694615] [http://www.ncbi.nlm.nih.gov/pubmed/21111746] is similar in overall fold to the six other human caspases for which structures are available, all of which are dimeric when active. The structure of ligand-free caspase-6 differs significantly from all other caspases because two novel extended helices are observed flanking the caspase-6 active site. All caspases share a common active-site cysteine–histidine dyad [http://www.ncbi.nlm.nih.gov/pubmed/12475198] and derive their name, cysteine aspartate proteases, from the presence of the catalytic cysteine at the active site and from their exquisite specificity for cleaving substrate proteins after aspartate residues [http://www.ncbi.nlm.nih.gov/pubmed/12680769]. Caspases catalyze cleavage of amide bonds via nucleophilic attack of the cysteine thiolate (Cys163 in caspase-6) at the substrate amide carbonyl. During catalysis, the histidine (His121 in caspase-6) activates the catalytic cysteine and a water molecule. Mutation of either of these residues results in loss of catalytic activity [http://www.ncbi.nlm.nih.gov/pubmed/8035875].
-
kDa) that belong to the family of intracellular lipid binding proteins (iLBP) which bind
+
Caspase-6 is expressed as inactive zymogen capable of dimerization. Caspase-6 has three reported cleavage sites that appear to be cleaved by autoproteolysis and or other caspases: D23 in the prodomain, D179 and D193 in the intersubunit linker [http://www.sciencedirect.com/science/article/pii/S0167488908004230]. The prodomain is released from the caspase dimer after cleavage leaving the active form of enzyme consists of two large and two small subunits. The large subunits contain the active site catalytic dyad residues, and the small subunits contain most of the dimer interface and the allosteric site.
-
small hydrophobic ligands. There are two types of CRABPs, CRABP I and CRABP II. They seem to play a role in controlling Retinoic Acid(RA)-mediated differentiation and proliferation processes [http://www.ncbi.nlm.nih.gov/pubmed/8756459?dopt=Abstract/]. During embryonic development, the spatial and temporal expression of the CRABP gene appears to be strictly regulated [http://www.ncbi.nlm.nih.gov/pubmed/2547683]. Therefore, it has been suggested that CRABP could be involved in the formation of gradients of RA across various developing tissues. Although the structure of CRABP I is similar to the cellular retinol-binding proteins, it binds only retinoic acid at specific sites within the nucleus, which may contribute to vitamin A-directed differentiation in epithelial tissue.
+
-
 
+
The regulation of caspase-6 activity is not well studied. More research on possible ways to regulate caspase-6 activity will provide additional basic understanding of the mechanism of caspase-6 activation. In cells, caspase-6 can be activated by removal of the part of caspase-6, the prodomain, along with cleavage at specific amino acid residue (aspartate 193). In addition, an alternatively spliced form of caspase-6, the caspase beta (C6β) isoform has been shown to inhibit caspase-6 activity [http://www.ncbi.nlm.nih.gov/pubmed/20682790]. Morover, reported structures of caspase-6 and its inhibitors (Ac-VEID-CHO [PDB ID: 3OD5] & (Z-VAD-FMK [PDB ID: 3QNW]) shed the some basic dynamics of caspase-6 activation including loop rearrangement near the active site [http://www.ncbi.nlm.nih.gov/pubmed/21820899] [http://www.nature.com/embor/journal/v11/n11/abs/embor2010141.html].
-
==Structure==
+
-
 
+
-
Proteins in iLBP family have very high structural conservation despite having very low sequence identities [http://www.ncbi.nlm.nih.gov/pubmed/14696180]. Similar to other members of the iLBP family, <scene name='CRABP_I_(_Cellular_Retinoic_Acid_Binding_Protein_)/Monomercrabpi/2'>CRABP I</scene> [http://www.pdb.org/pdb/explore/explore.do?structureId=1CBI (PDBID: 1CBI)] has two orthogonal five-stranded <scene name='CRABP_I_(_Cellular_Retinoic_Acid_Binding_Protein_)/Monomercrabpi/4'> β-sheets</scene> with a <scene name='CRABP_I_(_Cellular_Retinoic_Acid_Binding_Protein_)/Monomercrabpi/19'>helix-turn-helix</scene> between the first and the second β-strands,showing &alpha;+&beta;
+
-
secondary domains. It contains a very large solvent accessible central cavity that binds <scene name='CRABP_I_(_Cellular_Retinoic_Acid_Binding_Protein_)/1cbs_molecularplayground/5'>retinoic acid</scene> [http://www.pdb.org/pdb/explore/explore.do?structureId=1CBS (PDBID: 1CBS)]. This conserved <scene name='CRABP_I_(_Cellular_Retinoic_Acid_Binding_Protein_)/Monomercrabpi/6'>gap</scene> is contained between strand 4 and 5 and has no inter-strand hydrogen bonds but is compensated by the presence of ordered water molecules. The helix-turn-helix motif between the first and second strands acts as a <scene name='CRABP_I_(_Cellular_Retinoic_Acid_Binding_Protein_)/Monomercrabpi/7'>'lid'</scene> on the ligand binding pocket. Strands 7 and 8 are connected by the <scene name='CRABP_I_(_Cellular_Retinoic_Acid_Binding_Protein_)/Monomercrabpi/9'>omega loop</scene> which has variable lengths within the family. There are 15 fully <scene name='CRABP_I_(_Cellular_Retinoic_Acid_Binding_Protein_)/Monomercrabpi/10'>conserved</scene> residues in CRABP I, seven are found in the helix I and II and 5 are in the β-barrel closure [http://www.ncbi.nlm.nih.gov/pubmed/16477649].
+
-
 
+
-
The RA/CRABP interaction is predominantly hydrophobic, as the ligand forms ten
+
-
contacts with non-polar side chains and only one salt bridge. The β-barrel contains a poorly accessible hydrophobic ligand-binding cavity. For Chain A, the residues in <scene name='User:Jinyi_Lim/Sandbox_1/Active_sites_for_chain_a/2'>binding sites</scene> of CRABP I to RA correspond to PRO39,THR56, LEU120, ARG131, and TYR133. In case of Chain B, even though MET 27 is not one of the residues in chain B, it can be one of the the <scene name='User:Jinyi_Lim/Sandbox_1/Active_sites_for_chain_b/4'>binding sites </scene> to RA which is bound to PRO39, THR56, LEU120, ARG131, and TYR133 in chain B of CRABP I.
+
-
Comparison of the <scene name='User:Jinyi_Lim/Sandbox_1/Apo-form/2'>apo- </scene>and the <scene name='User:Jinyi_Lim/Sandbox_1/Holo-form/1'>holo-forms </scene> structure of the proteins in the iLBP family does not reveal a significant opening large enough to allow ligand entry and release
+
-
[http://www.jbc.org/content/267/33/23534.abstract]. Entry of RA into the cavity
+
-
of CRABPs is proposed to occur via a region of the protein comprising determinants
+
-
from the βC-D loop, the βE-F loop and the N-terminal region of helix II. This region of the protein referred to as the “portal” region of the protein has been extensively studied in other members of the iLBP family, in particular in the fatty acid binding protein, by X-ray crystallography, mutational analysis and multidimensional NMR [http://pubs.acs.org/doi/abs/10.1021/bi961890r].
+
==See Also==
==See Also==
-
* [http://en.wikipedia.org/wiki/CRABP1 Cellular retinoic acid-binding protein 1 at Wikipedia]
+
* [http://en.wikipedia.org/wiki/Caspase_6 Caspase-6 at Wikipedia]
-
 
+
-
==3D structure of Cellular retinoic acid-binding protein==
+
-
 
+
-
===CRABP I===
+
-
 
+
-
[[2cbr]] - hCRABP I – human<br />
+
-
[[1cbr]] - CRABP I + retinoic acid – mouse
+
-
 
+
-
===CRABP II===
+
-
 
+
-
[[2fs6]], [[2fs7]] - hCRABP II<br />
+
-
[[1blr]] - hCRABP II – NMR<br />
+
-
[[3fek]], [[3fel]], [[3fen]], [[3fa7]], [[3fa8]], [[3fa9]], [[3i17]], [[3d95]], [[3d96]], [[3d97]], [[2frs]] - hCRABP II (mutant) <br />
+
-
[[3f8a]], [[3f9d]], [[3fa6]], [[3cr6]], [[2g79]], [[2g7b]] – hCRABP II (mutant) + retinal analog<br />
+
-
[[3cwk]], [[2g78]] – hCRABP II (mutant) + retinoic acid<br />
+
-
[[2fr3]], [[2cbs]], [[3cbs]], [[1cbq]], [[1cbs]] – hCRABP II + retinoic acid<br />
+
-
[[3fep]] - hCRABP II (mutant) + ligand
+
-
 
+
 +
===Crystal structure of ligand free human caspase-6===
 +
[[2wdp]]
 +
===Crystal structure of human ligand-free mature caspase-6===
 +
[[3k7e]]
 +
===Crystal structure of Caspase-6 zymogen===
 +
[[3nr2]]
 +
=== Crystal structure of active caspase-6 bound with Ac-VEID-CHO===
 +
[[3od5]]
==References==
==References==
-
*[1] Venepally, P. ''et al''. Biochemistry. 35, 9974-9982 (1996) PMID: 8756459 [PubMed - indexed for MEDLINE]
+
*[1] Suzuki, A., Kusakai, G., Kishimoto, A., Shimojo, Y., Miyamoto, S., Ogura, T. et al. (2004). Regulation of caspase-6 and FLIP by the AMPK family member ARK5. Oncogene, 23, 7067–7075.
-
*[2] Vaessen, ''et al''. Differentiation. 40, 99-105 (1989). PMID: 2547683 [PubMed - indexed for MEDLINE]
+
*[2] S.B. De and W. Annaert, Proteolytic processing and cell biological functions of the amyloid precursor protein. J. Cell Sci., 113 Pt 11 (2000), pp. 1857–1870.
-
*[3] Gunasekaran, K, "et al". PROTEINS: Structure, Function, and Bioinformatics. PMID: 14696180
+
*[3] C.L. Wellington, L.M. Ellerby, A.S. Hackam, R.L. Margolis, M.A. Trifiro, R. Singaraja, K. McCutcheon, G.S. Salvesen, S.S. Propp, M. Bromm, K.J. Rowland, T. Zhang, D. Rasper, S. Roy, N. Thornberry, L. Pinsky, A. Kakizuka, C.A. Ross, D.W. Nicholson, D.E. Bredesen and M.R. Hayden, Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem., 273 (1998), pp. 9158–9167.
-
*[4] Marcelino, A, "et al". PROTEINS: Structure, Function, and Bioinformatics. PMID: 16477649 [Pubmed- indexed for MEDLINE]
+
*[4] C.L. Wellington, R. Singaraja, L. Ellerby, J. Savill, S. Roy, B. Leavitt, E. Cattaneo, A. Hackam, A. Sharp, N. Thornberry, D.W. Nicholson, D.E. Bredesen and M.R. Hayden, Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem., 275 (2000), pp. 19831–19838.
-
*[5] Xiao, H. and I. A. Kaltashov,J Am Soc Mass Spectrom. 16(6),869-79 (2005). | doi:10.1016/j.jasms.2005.02.020
+
*[5] Baumgartner, R., Meder, G., Briand, C., Decock, A., D'Arcy, A., Hassiepen, U. et al., The crystal structure of caspase-6, a selective effector of axonal degeneration, Biochem. J. 423 (2009), 429–439.
-
*[6] Krishnan, V. ''et al''. Biochemistry 39(31), 9119-9129 (2000)PMID: 10924105 [PubMed - indexed for MEDLINE]
+
*[6] S.V. Vaidya, E.M. Velázquez, G. Abbruzzese, J.A. Hardy, Substrate-Induced Conformational Changes Occur in All Cleaved Forms of Caspase-6. J. Mol. Bio., 406 (2011), 75-91.
-
*[7] Sacchettini, J. ''et al''. J Biol Chem. 267(33), 23534-23545 (1992)
+
*[7] Denault, J. B. & Salvesen, G. S. (2002). Caspases: keys in the ignition of cell death. Chem. Rev. 102, 4489–4500.
-
*[8] Hodsdon, M.''et al''. Biochemistry. 36(6), 1450-60(1997)| doi:10.1021/bi961890r
+
*[8] Chereau, D., Kodandapani, L., Tomaselli, K. J., Spada, A. P. & Wu, J. C. (2003). Structural and functional analysis of caspase active sites. Biochemistry, 42, 4151–4160.
-
*[9] Sjoelund, V. ''et al''. Biochemistry.46, 13382–13390 (2007) | doi: 10.1021/bi700867c
+
*[9] Wilson, K. P., Black, J. A., Thomson, J. A., Kim, E. E., Griffith, J. P., Navia, M. A. et al. (1994). Structure and mechanism of interleukin-1à converting enzyme. Nature, 370, 270–275.
 +
*[10] Klaiman, G., Champagne, N. & LeBlanc, A. C. (2009). Self-activation of Caspase-6 in vitro and in vivo: Caspase-6 activation does not induce cell death in HEK293T cells. Biochim. Biophys. Acta, 1793, 592–601.
 +
*[11] Lee AW, Champagne N, Wang X, Su XD, Goodyer C, LeBlanc AC, Alternatively spliced caspase-6B isoform inhibits the activation of caspase-6A, J Biol Chem. 285 (2010):31974-84.
 +
*[12] Muller, I. Lamers, MB., Ritchie AJ., Dominguez, C. Munoz-Sanjuan, I., Kiselyov, A. Structure of human caspase-6 in complex with Z-VAD-FMK: New peptide binding mode observed for the non-canonical caspase conformation, Bioorg Med Chem Lett., 18 (2011), 5244-7.
 +
*[13] Xiao-Jun Wang, Qin Cao, Xiang Li, Kai-Tuo Wang, Wei Mi, Yan Zhang, Lan-Fen Li, Andrea C LeBlanc& Xiao-Dong Su, Crystal structures of human caspase 6 reveal a new mechanism for intramolecular cleavage self-activation, EMBO reports 11 (2010), 841-847.
[[Category:Topic Page]]
[[Category:Topic Page]]

Current revision

One of the CBI Molecules being studied in the University of Massachusetts Amherst Chemistry-Biology Interface Program at UMass Amherst and on display at the Molecular Playground.

Caspase-6 with Z-VAD-FMK, an inhibitor of caspase-6 activity

Drag the structure with the mouse to rotate
PhD Chemistry Student

University of Massachusetts Amherst Protein Regulation/Structural Biology of Caspase

Molecular Playground banner:


Contents

Caspase-6 and Neurodegeneration

Cysteine aspartate proteases (caspases) play several key roles in cellular development, homeostasis, and a wide range of diseases. These proteases are normally expressed in cells as inactive precursor zymogens and get activated during processes such as cellular death pathway known as apoptosis [1]. Caspase-6 is particularly interesting since it has been implicated in neurodegenerative diseases including Alzheimer’s and Huntington’s Disease. Alzheimer’s Disease is the major cause of cognitive and cerebral deterioration in older adults. Caspase-6 has been shown to cut amyloid precursor protein (APP), at position 720 leading to the toxic fragment Jcasp, which is one of the fragments possibly responsible for causing the disease morphology [2]. Specific amino acid sequence (IVLD586G) is recognized by caspase-6 in mice with Huntington’s disease that give rise to the development of the behavioral and neuropathological features of the disease [3] [4]. Mutation of the caspase-6 site in mice model with Alzheimer’s and Huntington’s disease provides protection from the neural dysfunction, suggesting a causal relationship between caspase-6 cleavage and neurodegeneration.

Structure and Regulation

The structure of caspase-6 [5] [6] is similar in overall fold to the six other human caspases for which structures are available, all of which are dimeric when active. The structure of ligand-free caspase-6 differs significantly from all other caspases because two novel extended helices are observed flanking the caspase-6 active site. All caspases share a common active-site cysteine–histidine dyad [7] and derive their name, cysteine aspartate proteases, from the presence of the catalytic cysteine at the active site and from their exquisite specificity for cleaving substrate proteins after aspartate residues [8]. Caspases catalyze cleavage of amide bonds via nucleophilic attack of the cysteine thiolate (Cys163 in caspase-6) at the substrate amide carbonyl. During catalysis, the histidine (His121 in caspase-6) activates the catalytic cysteine and a water molecule. Mutation of either of these residues results in loss of catalytic activity [9]. Caspase-6 is expressed as inactive zymogen capable of dimerization. Caspase-6 has three reported cleavage sites that appear to be cleaved by autoproteolysis and or other caspases: D23 in the prodomain, D179 and D193 in the intersubunit linker [10]. The prodomain is released from the caspase dimer after cleavage leaving the active form of enzyme consists of two large and two small subunits. The large subunits contain the active site catalytic dyad residues, and the small subunits contain most of the dimer interface and the allosteric site.

The regulation of caspase-6 activity is not well studied. More research on possible ways to regulate caspase-6 activity will provide additional basic understanding of the mechanism of caspase-6 activation. In cells, caspase-6 can be activated by removal of the part of caspase-6, the prodomain, along with cleavage at specific amino acid residue (aspartate 193). In addition, an alternatively spliced form of caspase-6, the caspase beta (C6β) isoform has been shown to inhibit caspase-6 activity [11]. Morover, reported structures of caspase-6 and its inhibitors (Ac-VEID-CHO [PDB ID: 3OD5] & (Z-VAD-FMK [PDB ID: 3QNW]) shed the some basic dynamics of caspase-6 activation including loop rearrangement near the active site [12] [13].

See Also

Crystal structure of ligand free human caspase-6

2wdp

Crystal structure of human ligand-free mature caspase-6

3k7e

Crystal structure of Caspase-6 zymogen

3nr2

Crystal structure of active caspase-6 bound with Ac-VEID-CHO

3od5

References

  • [1] Suzuki, A., Kusakai, G., Kishimoto, A., Shimojo, Y., Miyamoto, S., Ogura, T. et al. (2004). Regulation of caspase-6 and FLIP by the AMPK family member ARK5. Oncogene, 23, 7067–7075.
  • [2] S.B. De and W. Annaert, Proteolytic processing and cell biological functions of the amyloid precursor protein. J. Cell Sci., 113 Pt 11 (2000), pp. 1857–1870.
  • [3] C.L. Wellington, L.M. Ellerby, A.S. Hackam, R.L. Margolis, M.A. Trifiro, R. Singaraja, K. McCutcheon, G.S. Salvesen, S.S. Propp, M. Bromm, K.J. Rowland, T. Zhang, D. Rasper, S. Roy, N. Thornberry, L. Pinsky, A. Kakizuka, C.A. Ross, D.W. Nicholson, D.E. Bredesen and M.R. Hayden, Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem., 273 (1998), pp. 9158–9167.
  • [4] C.L. Wellington, R. Singaraja, L. Ellerby, J. Savill, S. Roy, B. Leavitt, E. Cattaneo, A. Hackam, A. Sharp, N. Thornberry, D.W. Nicholson, D.E. Bredesen and M.R. Hayden, Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem., 275 (2000), pp. 19831–19838.
  • [5] Baumgartner, R., Meder, G., Briand, C., Decock, A., D'Arcy, A., Hassiepen, U. et al., The crystal structure of caspase-6, a selective effector of axonal degeneration, Biochem. J. 423 (2009), 429–439.
  • [6] S.V. Vaidya, E.M. Velázquez, G. Abbruzzese, J.A. Hardy, Substrate-Induced Conformational Changes Occur in All Cleaved Forms of Caspase-6. J. Mol. Bio., 406 (2011), 75-91.
  • [7] Denault, J. B. & Salvesen, G. S. (2002). Caspases: keys in the ignition of cell death. Chem. Rev. 102, 4489–4500.
  • [8] Chereau, D., Kodandapani, L., Tomaselli, K. J., Spada, A. P. & Wu, J. C. (2003). Structural and functional analysis of caspase active sites. Biochemistry, 42, 4151–4160.
  • [9] Wilson, K. P., Black, J. A., Thomson, J. A., Kim, E. E., Griffith, J. P., Navia, M. A. et al. (1994). Structure and mechanism of interleukin-1à converting enzyme. Nature, 370, 270–275.
  • [10] Klaiman, G., Champagne, N. & LeBlanc, A. C. (2009). Self-activation of Caspase-6 in vitro and in vivo: Caspase-6 activation does not induce cell death in HEK293T cells. Biochim. Biophys. Acta, 1793, 592–601.
  • [11] Lee AW, Champagne N, Wang X, Su XD, Goodyer C, LeBlanc AC, Alternatively spliced caspase-6B isoform inhibits the activation of caspase-6A, J Biol Chem. 285 (2010):31974-84.
  • [12] Muller, I. Lamers, MB., Ritchie AJ., Dominguez, C. Munoz-Sanjuan, I., Kiselyov, A. Structure of human caspase-6 in complex with Z-VAD-FMK: New peptide binding mode observed for the non-canonical caspase conformation, Bioorg Med Chem Lett., 18 (2011), 5244-7.
  • [13] Xiao-Jun Wang, Qin Cao, Xiang Li, Kai-Tuo Wang, Wei Mi, Yan Zhang, Lan-Fen Li, Andrea C LeBlanc& Xiao-Dong Su, Crystal structures of human caspase 6 reveal a new mechanism for intramolecular cleavage self-activation, EMBO reports 11 (2010), 841-847.

Proteopedia Page Contributors and Editors (what is this?)

Kevin Buadlart Dagbay, Eric Martz, Jaime Prilusky

Personal tools